Addex Therapeutics, Ltd. - ADXN EV/EBITDA Multiple
Addex Therapeutics (ADXN) is implementing software robots to analyze clinical trial datasets and is testing automated screening stations. The business relies on IT platforms that model nervous system modulators, eliminating routine labor for personnel. The strategy focuses on developing mild drugs to treat dystonia and Parkinson's disease. This price chart shows EV/EBITDA at 0.00.
Analytical breakdowns for addextherapeutics.com (ADXN)
- current price and projected stock value:
- issuer market value details:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Equity Ratio Addex Therapeutics|ADXN - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Addex Therapeutics Ltd|ADXN - Aggregate Debt Obligations|Debts to Book Capitalization Addex|ADXN - Long-Term Debt|Company Short-Term Debt Addex Therapeutics|Quick Ratio addextherapeutics.com
- net income and valuation multiples indicators:
ADXN - Net Profit|Expected Profit Addex Therapeutics|ADXN - Market Cap to Net Income|Forward P/E Multiple Addex Therapeutics|ADXN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Addex|ADXN - Operating profit EBITDA|Net earnings per share for the last 12 months Addex Therapeutics|ADXN - Earnings per share for the last four quarters|Quarterly EPS earnings growth addextherapeutics.com|ADXN - Expected net earnings per share growth this year|Earnings growth forecast for next year Addex Therapeutics
Summary company analysis:Addex Therapeutics, Ltd. ADXN
To build a defensive portfolio, fundamental screening requires analyzing business value relative to operating profit. The EV/EBITDA ratio for Addex Therapeutics (ADXN) correlates the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization, thereby determining the asset payback period. For Addex Therapeutics (ADXN), the trend of this indicator reflects market expectations regarding the success of Parkinson's disease drugs and the effectiveness of patent protection.
Competitor analysis
EV/EBITDA Multiple BIIB (Biogen Corp)|NBIX: Enterprise Value to Operating Income Before Depreciation|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation XENE|Enterprise Value to EBITDA Ratio VKTX|SUPN: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|Enterprise Value to Operating Income Before Depreciation Ratio DNLI|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Trevi Corp|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|anavex.com - Business Value to Operating Income Before Depreciation|CBLL (CeriBell) - EV/EBITDA Multiple|EV/EBITDA Multiple Prothena Corporation PLC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple OMER (Omeros)|neurogene.com (NGNE) - Company Value to EBITDA|ACIU: Enterprise Value to EBITDA Ratio|VYGR - EV/EBITDA Multiple|NMRA (Neumora Therapeutics Inc) - Enterprise Value to EBITDA Ratio|SCLX: Enterprise Value to Operating Income Before Depreciation Ratio|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Alpha Cognition Corp (ACOG) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CGTX|Enterprise Value to EBITDA Ratio Inhibikase Therapeutics Inc IKT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|Coya - EV/EBITDA Multiple|VTGN - EV/EBITDA Multiple|OVID: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ABOS|Enterprise Value to EBITDA Ratio CRVO|Enterprise Value to Operating Income Before Depreciation ATHE (Alterity Therapeutics Ltd)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|pepgen.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|RLMD: Enterprise Value to Operating Income Before Depreciation|Annovis Bio Corp - EV/EBITDA Multiple|Company Value to EBITDA Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience, Inc) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|RVPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia Inc (MTVA)|NRXS - Company Value to EBITDA|EV/EBITDA Multiple HSDT (Helius Medical Technologies)|EV/EBITDA Multiple Passage Bio Inc. PASG|Neuphoria - EV/EBITDA Multiple|NERV (Minerva Neurosciences Inc) - Enterprise Value to Operating Income Before Depreciation|ATHA: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ALZN|CYCN (Cyclerion Therapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Protagenic PTIX|Enterprise Value to EBITDA Ratio KTTA (Pasithea Therapeutics)|cortigent.com - Enterprise Value to Operating Income Before Depreciation|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA: Enterprise Value to EBITDA Ratio|chromocell.com - Enterprise Value to Operating Income Before Depreciation Ratio|ELYM: EV/EBITDA Multiple|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA cerevel.com (CERE)
